Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Luteolin Nanocapsules Demonstrate Effective Anticancer Activity in Mouse Model

By BiotechDaily International staff writers
Posted on 23 Jan 2014
Image: Cellular uptake of nanoparticles encapsulating both dye and luteolin (Photo courtesy of Winship Cancer Institute of Emory University).
Image: Cellular uptake of nanoparticles encapsulating both dye and luteolin (Photo courtesy of Winship Cancer Institute of Emory University).
Nanocapsules containing the natural antioxidant luteolin were found to be significantly more effective than natural luteolin in inhibiting growth of cancer cells both in culture and in a mouse xenograft model.

Luteolin is a flavone, a type of flavonoid, and, like all flavonoids, has a yellow crystalline appearance. Dietary sources include celery, green pepper, thyme, dandelion, chamomile tea, carrots, olive oil, peppermint, rosemary, navel oranges, and oregano. Luteolin reportedly acts as a monoamine transporter activator, and is one of the few chemicals demonstrated to possess this property. Experiments have suggested that luteolin may inhibit the development of some types of skin cancer.

In the current study, investigators at Emory University (Atlanta, GA, USA) formulated water-soluble polymer-encapsulated Nano-Luteolin from luteolin, and studied its anticancer activity against lung cancer and head and neck cancer. The low water solubility of luteolin, which hampers its use in treatment due to problems of low bioavailability, poor systemic delivery, and low efficacy, led the investigators to choose a nanocapsule format for their experiments.

Results published in the January 2014 issue of the journal Cancer Prevention Research revealed that like luteolin, Nano-Luteolin inhibited the growth of lung cancer cells (H292 cell line) and squamous cell carcinoma of head and neck (SCCHN) cells (Tu212 cell line). In vivo studies using a tumor xenograft mouse model demonstrated that Nano-Luteolin had a significant inhibitory effect on the tumor growth of SCCHN in comparison to luteolin.

"Our results suggest that nanoparticle delivery of naturally occurring dietary agents like luteolin has many advantages," said senior author Dr. Dong Moon Shin, professor of hematology and medical oncology at Emory University. "By using a high concentration of luteolin in the blood, we were better able to inhibit the growth of cancer cells."

Related Links:

Emory University


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Blocking the activity of HSP101 may imprison the malaria parasite inside its protective vacuole within the red blood cell. In the electron micrograph, the malaria parasites appear in blue and uninfected red blood cells are shown in red (Photo courtesy of the [US] National Institute of Allergy and Infectious Diseases).

Heat Shock Protein Plays Critical Role in Malaria Parasite Protein Trafficking

A pair of recent papers described the molecular operators that enable the malaria parasite Plasmodium falciparum to export a large variety of proteins across the parasitophorous vacuolar membrane (PVM)... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.